Metacrine, Inc.
MTCRDelisted Mar 3, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001634379
Metacrine, Inc. was delisted on Mar 3, 2023; its insiders filed their last Form 4 on Mar 24, 2023; 29 institutions reported holding it in 13F filings for Q4 2022, worth $7.29M in total; no superinvestor held it.
Q2 2022 vs. Q1 2022
How the institutions holding Metacrine, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 31 | 25 | −6 |
| Shares | 6.29M | 6.12M | −163.1K (−2.6%) |
| Value | $3.83M | $3.06M | −$776.0K (−20.2%) |
New holders (2)
Institutions that held Metacrine, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 28,468 | $14.0K | 0.00% |
| Credit Suisse AG | 244 | $0 | 0.00% |
Sold out (8)
Institutions that held Metacrine, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Bank of America Corp | 263,340 | $161.0K |
| Citadel Advisors LLC | 41,144 | $25.0K |
| Two Sigma Investments, LP | 23,035 | $14.0K |
| Goldman Sachs Group Inc | 15,744 | $10.0K |
| Ergoteles LLC | 12,432 | $8.00K |
| Barclays PLC | 11,710 | $7.00K |
| Citigroup Inc | 2,982 | $2.00K |
| JPMorgan Chase & Co | 1,038 | $1.00K |